Alternate site health provider Option Care Health (NASDAQ:OPCH) will be reporting earnings tomorrow before market open. Here’s what to look for.
Option Care Health beat analysts’ revenue expectations by 5% last quarter, reporting revenues of $1.28 billion, up 17% year on year. It was an exceptional quarter for the company, with a solid beat of analysts’ EPS estimates and full-year revenue guidance beating analysts’ expectations.
Is Option Care Health a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Option Care Health’s revenue to grow 14.1% year on year to $1.28 billion, improving from the 9.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.36 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Option Care Health has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2.4% on average.
Looking at Option Care Health’s peers in the senior health, home health & hospice segment, some have already reported their Q4 results, giving us a hint as to what we can expect. AdaptHealth posted flat year-on-year revenue, beating analysts’ expectations by 3.3%, and Addus HomeCare reported revenues up 7.5%, topping estimates by 2.7%.
Read our full analysis of AdaptHealth’s results here and Addus HomeCare’s results here.
Stocks generally had a good 2024. The Fed fought high inflation and won without sending the economy into a recession, otherwise lovingly known as a soft landing. The US Central Bank is now cutting rates. That, plus the election of Donald Trump in November 2024, sent markets even higher, and while some of the senior health, home health & hospice stocks have shown solid performance, the group has generally underperformed, with share prices down 5.4% on average over the last month. Option Care Health is up 2.1% during the same time and is heading into earnings with an average analyst price target of $31.56 (compared to the current share price of $32.07).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
